TAG announced today the appointment of Adam Ortega as Communications Director. Adam brings experience in nonprofit marketing and public health and will lead TAG’s communications strategy to expand its reach and impact, and will deepen TAG as a leading voice in treatment advocacy, research, and community engagement on our work to end HIV, TB, and HCV as epidemics.
TAG condemns the United States’ war in Iran and neighboring countries. At a time when U.S. investment in public health is being slashed, the Trump administration has chosen to spend billions of dollars per day on weapons used in a war of choice for which no credible rationale has been proposed. Our government should invest in our communities by spending funds that were already appropriated and illegally impounded by the White House Office of Management and Budget to keep people healthy, rather than starting new wars that put the entire world’s health at risk.
This year revealed how far this administration is willing to go in undermining public health. The White House refused to recognize World AIDS Day. Global and domestic HIV, TB, and HCV programs were directly threatened, and many were terminated. Senior CDC leaders resigned rather than carry out political firings or oversee the degradation of national vaccine guidance. And in August, a vigilante encouraged by political rhetoric fired nearly 500 rounds into the CDC campus in Atlanta and killed a police officer. The President has still not publicly acknowledged the attack.
TAGLine 2025 documents a year of action as Treatment Action Group defended science, confronted attacks on public health, and fought to protect communities impacted by HIV, TB, and HCV.
TAG signed onto this letter sponsored by the HIV Legal Network to Canadian Prime Minister Mark Carney about the importance of strong investments in health and community systems as they reinforce global health security, which in turn keeps everyone safe.
A new report released today by Treatment Action Group (TAG) and Stop TB Partnership found that cumulative funding for tuberculosis (TB) research and development (R&D) in 2023 reached only 24% of the annual $5 billion funding target agreed by countries at the United Nations High-Level Meeting (HLM) on TB in September 2023.
In advance of the 52nd Meeting of the Board of the Global Fund to Fight AIDS, Tuberculosis, and Malaria (the Global Fund) and the 2024 Union World Conference on Lung Health, Treatment Action Group (TAG) releases this statement in response to ongoing conversations about the Global Fund’s program allocations for HIV, tuberculosis (TB), and malaria.
Treatment Action Group (TAG) is deeply concerned by the reported decrease in domestic funding for tuberculosis (TB) services announced today in the World Health Organization's 2024 Global Tuberculosis Report.
In response to disheartening news of the proposed $5.3 million cut in HIV/AIDS funding by the Adams administration, we at Treatment Action Group (TAG) express our resolute opposition, in solidarity with our partner organizations that would be harmed by the egregious, unconscionable cuts to HIV services and programs in New York City.
A new report released today by Treatment Action Group (TAG) and the Stop TB Partnership has found that cumulative funding for tuberculosis (TB) research and development (R&D) over the past five years is falling shockingly short of commitments.